Medivation Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Medivation Reports First Quarter 2015 Financial Results
May 8, 2015 9:45 AM EDT
Leerink Partners maintains an Outperform rating on Medivation, Inc. (NASDAQ: MDVN), with their price target set at $128. Leerink believes that the demand for Xtandi appears to be solid, and expects a continued uptake of Xtandi over the rest of the year. MDVN reported US Xtandi sales were $224M in 1Q15. While this was in the... More
May 8, 2015 9:40 AM EDT
UBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from $130.00) despite a miss on US Xtandi sales by $14m. The firm remain encouraged by the results since only nominal double-digit growth is required to beat 2015... More
May 7, 2015 4:17 PM EDT
Medivation (NASDAQ: MDVN) reported Q1 EPS of $0.17, $0.10 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $127.8 million versus the consensus estimate of $149 million.
U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. prior year). On its February 25, 2015 earnings call, Medivation stated its... More
